润达医疗
Shanghai Runda Medical Technology Co., Ltd. belongs to the Health Care sector. Filings by its managers are published through SSE / SZSE (CSRC). 2 insiders have disclosed 2 filings since 18 October 2025.
No insider bought on the market over the period, while 2 insiders filed 2 sales totalling €7.4M. At €6.2M, the sale published on 14 January 2026 by 朱文怡 is the largest of the period.
Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (515 companies, median 2 filings), a count of 2 filings is typical. Over the whole record (from 2021), the tally stands at no purchases and 11 sales.
In the same sector, recent insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. also feature in our signals. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
11 of 11 declarations
润达医疗 is a company in the healthcare and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and manufacturing of medical devices and innovative health solutions.